Zura Bio price target lowered to $16 from $17 at Oppenheimer

Oppenheimer lowered the firm’s price target on Zura Bio (ZURA) to $16 from $17 and keeps an Outperform rating on the shares after the company reported Q2 financial results and provided an update on their ongoing clinical studies of tibulizumab, with the global Phase 2 TibuSHIELD study in HS having launched in May. The firm’s reported Q2 ending cash of $154.5M is anticipated to support operations through 2027 and readouts from both ongoing studies of tibulizumab.